Key Points
- EVP William Andrew Macan sold 16,005 shares on March 19 at an average price of $1.34 (proceeds $21,446.70), reducing his stake by 1.75% to 897,270 shares after several other February sales.
- Neuronetics beat near-term estimates on March 17 with revenue of $41.78M and EPS of ($0.10), and provided a 2026 outlook, but the stock opened around $1.40 and was trading down about 3.8%.
- Market sentiment is mixed: analysts cut targets (Canaccord $7→$3; average target $3) and insiders sold ~78k shares, while major shareholder Jorey Chernett has been buying aggressively, signaling competing signals for the stock.
Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) EVP William Andrew Macan sold 16,005 shares of the firm's stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $1.34, for a total transaction of $21,446.70. Following the completion of the sale, the executive vice president owned 897,270 shares in the company, valued at $1,202,341.80. The trade was a 1.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
William Andrew Macan also recently made the following trade(s):
- On Thursday, February 26th, William Andrew Macan sold 3,427 shares of Neuronetics stock. The stock was sold at an average price of $1.35, for a total transaction of $4,626.45.
- On Thursday, February 12th, William Andrew Macan sold 14,120 shares of Neuronetics stock. The shares were sold at an average price of $1.65, for a total value of $23,298.00.
- On Tuesday, February 10th, William Andrew Macan sold 3,485 shares of Neuronetics stock. The shares were sold at an average price of $1.55, for a total value of $5,401.75.
Neuronetics Trading Down 3.8%
NASDAQ:STIM opened at $1.40 on Thursday. The stock has a 50-day simple moving average of $1.57 and a 200-day simple moving average of $1.98. The stock has a market cap of $96.99 million, a P/E ratio of -2.37 and a beta of 0.87. Neuronetics, Inc. has a 1 year low of $0.80 and a 1 year high of $4.85. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.87 and a current ratio of 2.02.
Neuronetics (NASDAQ:STIM - Get Free Report) last issued its earnings results on Tuesday, March 17th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. The business had revenue of $41.78 million for the quarter, compared to analyst estimates of $40.84 million. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%. As a group, analysts anticipate that Neuronetics, Inc. will post -1.13 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on STIM shares. Canaccord Genuity Group decreased their price objective on shares of Neuronetics from $7.00 to $3.00 and set a "buy" rating for the company in a research note on Thursday, March 19th. Wall Street Zen lowered shares of Neuronetics from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Neuronetics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Neuronetics currently has an average rating of "Hold" and an average price target of $3.00.
Get Our Latest Stock Report on STIM
Institutional Investors Weigh In On Neuronetics
Large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd grew its position in Neuronetics by 2,667.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 69,756 shares of the company's stock valued at $96,000 after buying an additional 67,235 shares during the last quarter. Aristides Capital LLC acquired a new stake in shares of Neuronetics in the 4th quarter worth $188,000. Invesco Ltd. boosted its holdings in shares of Neuronetics by 80.0% in the fourth quarter. Invesco Ltd. now owns 58,940 shares of the company's stock valued at $81,000 after acquiring an additional 26,194 shares in the last quarter. XTX Topco Ltd boosted its holdings in shares of Neuronetics by 992.6% in the fourth quarter. XTX Topco Ltd now owns 314,194 shares of the company's stock valued at $434,000 after acquiring an additional 285,438 shares in the last quarter. Finally, Caption Management LLC increased its stake in shares of Neuronetics by 571.4% during the fourth quarter. Caption Management LLC now owns 92,501 shares of the company's stock worth $128,000 after acquiring an additional 78,723 shares during the period. Hedge funds and other institutional investors own 53.59% of the company's stock.
Key Headlines Impacting Neuronetics
Here are the key news stories impacting Neuronetics this week:
- Positive Sentiment: Major shareholder Jorey Chernett has been buying aggressively (most recently 169,472 shares at ~$1.41; multiple prior purchases totaling >1.5M shares over several days), signaling insider confidence and adding a strong demand signal. Major Shareholder Jorey Chernett Buys 169,472 Shares
- Positive Sentiment: Company reported higher revenue and a narrower loss and provided a 2026 outlook, which supports fundamentals after the March 17 quarter. That underlying operational improvement is a bullish datapoint for longer-term recovery. Neuronetics reports higher revenue, narrows loss, sets 2026 outlook
- Neutral Sentiment: Board/leadership change — Dan Reuvers has been appointed CEO, succeeding Keith Sullivan; leadership transitions can be neutral-to-positive depending on execution and investor confidence. Neuronetics appoints Dan Reuvers as CEO
- Neutral Sentiment: Reported short-interest entries for late March show anomalous/zero values across several feeds (likely data/reporting artifacts), so short-interest signals are currently unreliable as a trading driver. (No actionable change tied to clean short-interest data.)
- Negative Sentiment: Several insiders (EVPs William Macan and Steven Pfanstiel; Director Keith Sullivan) sold shares (~78k combined) at roughly $1.34 per share, modestly reducing insider ownership and potentially adding selling pressure. SEC filing (insider sales)
- Negative Sentiment: Analyst actions are mixed-to-negative: Canaccord cut its price target (from $7 to $3) despite a buy rating; other shops have downgraded or maintained sell views, which can pressure sentiment and limit near-term upside. (MarketBeat/analyst notes)
Neuronetics Company Profile
(
Get Free Report)
Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company's flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.
Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
